Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zomedica Corp. Common Shares (NY: ZOM )

0.0973 UNCHANGED
Last Price Updated: 8:00 PM EST, Mar 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zomedica Corp. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development
Via ACCESSWIRE
Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushing’s Disease in Horses
Via ACCESSWIRE
Zomedica Provides Corporate Update
Via ACCESSWIRE
7 Biotech Stocks to Sell in September Before They Crash & Burn
These are just a few of the top biotech stocks to sell today - especially with each of the firms dealing with legitimate issues. 
Via InvestorPlace
Why Shares of Zomedica Were Zooming Monday
Investors bought back into the stock after it fell to its lowest point in two months. 
Via The Motley Fool
Zomedica Closes Acquisition of Structured Monitoring Products Adding Revolutionary VetGuardian Touchless Vital Signs Monitor to Product Portfolio
Via ACCESSWIRE
Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity
Via ACCESSWIRE
Zomedica to Present at Sidoti Virtual Investor Conference August 16-17
Via ACCESSWIRE
Zomedica to Host Second Quarter Financial Results Call on August 10
Via ACCESSWIRE
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
RedChip Launches 'Small Stocks, Big Money' Podcast
Via ACCESSWIRE
Zomedica Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services
Via ACCESSWIRE
Zomedica to Participate in the Lytham Partners Spring 2023 Investor Conference
Via ACCESSWIRE
The 7 Most Promising Penny Stocks to Buy in May 2023
Although extremely low-priced securities often present high risk, these are the most promising penny stocks to buy in May. 
Via InvestorPlace
Zomedica Announces Record First Quarter 2023 Financial Results: Revenue up 45% to $5.5 Million; Strong 70% Gross Margin & $147.5 Million in Liquidity
Via ACCESSWIRE
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
Zomedica Exercises Option to Acquire Structured Monitoring Products
Via ACCESSWIRE
Zomedica to Host First Quarter Financial Results Call on May 11
Via ACCESSWIRE
7 Small-Cap Biotech Stocks with Massive Potential
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
Via InvestorPlace
Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
7 Best Penny Stocks Under $3 to Buy in April
If you have the audacity to consider ultra-speculative opportunities, these ideas for best penny stocks under $3 might be appealing. 
Via InvestorPlace
Zomedica Corp. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Zomedica Appoints New Chief Financial Officer
Via ACCESSWIRE
Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity - Revenue up 361% from 2021 through combination of acquisitions and organic growth
Via ACCESSWIRE
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
Zomedica to Host Fourth Quarter and Fiscal Year 2022 Financial Results Call on March 15
Via ACCESSWIRE
Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022
Via ACCESSWIRE
Zomedica Interview To Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
RedChip CEO Dave Gentry Invited to Join Forbes Business Council
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.